ZYUS Life Sciences Corporation has announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,616,704, entitled cannabichromene (CBC) formulation for pain management. The patent, held by ZYUS' wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No. PCT/CA2021/050430 and covers a novel, non-intoxicating approach to pain management.

This represents the company's second US patent in pain management, further strengthening its Intellectual Property (IP) portfolio. The company's first US patent supports ZYUS' lead drug candidate, Trichomylin softgel capsules, a proprietary fixed-dose combination for pain management by delivering a balanced ratio of cannabinoids, which includes CBC.

The newly issued patent relates to the company's second drug candidate, further expanding its pipeline of novel, proprietary, non-opioid therapies and supports ongoing clinical research targeting neuropathic pain, including peripheral neuropathy, such as diabetic and cancer-related neuropathies. These indications are consistent with those covered under the company's first patent, reinforcing ZYUS' focused approach to pain management.

The issuance of the US patent further strengthens the continued development of the company's second drug candidate, for which Investigational New Drug (IND)-enabling studies have been completed to support the potential initiation of clinical trials in the US. The patent provides additional IP protection alongside potential regulatory exclusivity for CBC, whether as monotherapy or within its lead drug product, Trichomylin softgel capsules, subject to regulatory determination by FDA at the time of marketing authorisation.

Brent Zettl, President and CEO, ZYUS, said, "The issuance of this US patent further validates our commitment to advancing a differentiated portfolio of novel non-opioid pain drugs. We remain focused on developing innovative treatment options to address significant unmet needs in chronic and neuropathic pain."